Contineum Therapeutics, Inc. Class A (CTNM) Stock Statistics & Valuation Metrics

Contineum Therapeutics, Inc. Class A has a market cap or net worth of $506.16M. The enterprise value is $420.26M.

Contineum Therapeutics, Inc. Class A has 32,673,534 shares outstanding. The number of shares has decreased by -2.65% in one year.

Contineum Therapeutics, Inc. Class A’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.28%.

The current PE Ratio of Contineum Therapeutics, Inc. Class A is ―. Contineum Therapeutics, Inc. Class A’s PEG ratio is 11.51.

In the last 12 months, Contineum Therapeutics, Inc. Class A had revenue of 0.00 and earned -59.98M in profits. Earnings per share was -2.17.

In the last 12 months, operating cash flow was -55.31M and capital expenditures -231.00K, giving a free cash flow of -55.54M billion.

Contineum Therapeutics, Inc. Class A pays an annual dividend of ―, resulting in a dividend yield of ―

Contineum Therapeutics, Inc. Class A upcoming earnings date is May 14, 2026, After Close (Confirmed).

Contineum Therapeutics, Inc. Class A as a current ratio of 27.50, with Debt / Equity ratio of 3.16%

In the past 12 months, Contineum Therapeutics, Inc. Class A has paid 0.00 in taxes.

Contineum Therapeutics, Inc. Class A EV to EBITDA ratio is -3.66, with an EV/FCF ratio of -4.49.

Contineum Therapeutics, Inc. Class A has $262.90M in cash and marketable securities with $8.25M in debt, giving a net cash position of $254.65M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Contineum Therapeutics, Inc. Class A is $22.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy